DHX9 has been reported to inhibit EMT in A549 lung adenocarcinoma cells, is overexpressed in several cancer types, including lung, breast, and colorectal cancer, and is implicated in the TGFβ pathway (47, 81). Here, DHX9 is linked to cancer.